Compare Response Plus Holding PJSC with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
AED 438 Million (Micro Cap)
9.00
NA
0.00%
0.08
20.33%
1.78
Revenue and Profits:
Net Sales:
75 Million
(Quarterly Results - Jun 2022)
Net Profit:
6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-44.42%
0%
-44.42%
6 Months
-45.11%
0%
-45.11%
1 Year
-45.11%
0%
-45.11%
2 Years
-43.26%
0%
-43.26%
3 Years
-77.02%
0%
-77.02%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Response Plus Holding PJSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
183.90%
EBIT Growth (5y)
75.05%
EBIT to Interest (avg)
33.06
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
1.28
Tax Ratio
11.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.68%
ROE (avg)
16.07%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
1.78
EV to EBIT
8.35
EV to EBITDA
6.23
EV to Capital Employed
1.72
EV to Sales
0.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
20.61%
ROE (Latest)
20.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
516.10
455.00
13.43%
Operating Profit (PBDIT) excl Other Income
73.60
79.30
-7.19%
Interest
2.80
2.80
Exceptional Items
0.00
0.00
Consolidate Net Profit
50.00
53.50
-6.54%
Operating Profit Margin (Excl OI)
106.30%
142.00%
-3.57%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 13.43% vs 31.73% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -6.54% vs 8.30% in Dec 2024
About Response Plus Holding PJSC 
Response Plus Holding PJSC
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






